Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Shareholder Meeting (November 2023)
10 slides from Emvision Medical Devices's shareholder meeting presentation, Nov 15, 2023
Slide 1: AGM 2023 CEO Presentation
www.emvision.com.au AGM 2023 CEO PRESENTATION NOVEMBER 2023 ASX:EMV
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by EMVision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in EMVision in any
Slide 3: Meet the Team
MEET THE TEAM SIGNIFICANT MEDICAL DEVICE DEVELOPMENT AND GLOBAL COMMERCIALISATION EXPERTISE ACROSS THE GROUP EXECUTIVE LEADERSHIP TEAM BOARD OF DIRECTORS Scott Kirkland John Keep As former CEO of Queensland Diagnostic Imaging, Sales and marketing executive, former Head of CEO and Managing Independen
Slide 4: Our vision is to reduce the global burden of stroke and other time sensitive medical emergencies
OUR VISION IS TO REDUCE THE GLOBAL BURDEN OF STROKE AND OTHER TIME SENSITIVE MEDICAL EMERGENCIES FIRST INDICATION - STROKE SECOND INDICATION - TRAUMATIC BRAIN INJURY (TBI) • 1 in 4 adults will have a stroke in their lifetime • An estimated 50-60 million people, worldwide, will suffer a TBI this year
Slide 5: EMVision's portfolio of world first point-of-care brain scanners is the solution
EMVISION’S PORTFOLIO OF Neuroimaging as is WORLD FIRST POINT-OF- accessible today. CARE BRAIN SCANNERS IS • Large • Expensive THE SOLUTION • For most part stationary • Ionizing radiation (CT) and ferromagnetism (MRI) • Requires special infrastructure • Requires specialist operators EMVision, Neuroim
Slide 6: 2023 Highlights
2023 HIGHLIGHTS 1st Gen bedside scanner undergoing Encouraging interim algorithm Advanced first responder (Gen 2) $6.05m in non-dilutive grant funds multi-site clinical trials at leading testing for ‘Blood or not’ prototype assembled for bench received thus far in 2023 to support comprehensive strok
Slide 7: How EMVision's imaging comes together
HOW EMVISION’S IMAGING COMES Signals obtained in a matter of minutes TOGETHER P(Haemorrhage) EMVision is developing a Detection & Classification P(Ischemia), other What is it? P = Probability “zero to one” medical imaging technology with a series of algorithms Localization of abnormality that are co
Slide 8: Latest patient imaging case studies
LATEST PATIENT IMAGING CASE STUDIES In these examples from EMVision’s multi-site clinical trials (pre-validation phase), the EMVision algorithms are able to detect, correctly localize by quadrant (‘heatmap’ of greatest intensity) and classify intracerebral hemorrhage (‘blood or not’) and other (‘no
Slide 9: Pathway to market entry (Gen 1 during FY25)
PATHWAY TO MARKET ENTRY (GEN 1 DURING FY25) Notified Body Conformity EU GEN 1 Multi-site clinical trials Assessment (CE Marking) Pre-validation phase – Objectives: hardware verification, usability, safety, data for AI models 3 key sites activated (Liverpool, Royal Melbourne and Princess Alexandra Ho
Slide 10: Set up for success
SET UP FOR SUCCESS KEY UPCOMING CATALYSTS ✓ We have assembled a team of medtech experts that have successfully done this before and created significant shareholder value Generate pre-validation and validation clinical trial data, achieving endpoints and recruitment ✓ We have compelling support from
Emvision Medical Devices — Shareholder Meeting (November 2023) on 6ix